We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
86 own
22 watching
Current Price
$41.5
$-1.15
(-2.7%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
7,356.02M
52-Week High
89.99
52-Week Low
29.27
Average Volume
1.25M
Dividend Yield
--
P/E Ratio
--
Market Capitalization7,356.02M
52-Week High89.99
52-Week Low29.27
Average Volume1.25M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company develops the Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
2 months ago
Exact Sciences (NASDAQ:EXAS Get Rating) and Veracyte (NASDAQ:VCYT Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership...
PR Newswire
2 months ago
Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical...
Ticker Report
2 months ago
Raymond James Financial Services Advisors Inc. raised its stake in shares of Exact Sciences Co. (NASDAQ:EXAS Get Rating) by 12.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,463 shares of the medical ...
TheStreet.com
3 months ago
The synthetic biology pioneer has underpromised and over-delivered on biosecurity revenue in 2022. Here's what comes next.The synthetic biology pioneer has underpromised and over-delivered on biosecurity revenue in 2022. Here's what comes next.Companies across the economy have reduced full-year 2022...
PR Newswire
4 months ago
Exact Sciences schedules second quarter 2022 earnings call Exact Sciences schedules second quarter 2022 earnings call PR Newswire MADISON, Wis., July 8, 2022 MADISON, Wis., July 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$41.5
$-1.15
(-2.7%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00